Lactobacilli and vaginal host defense: activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF-kappaB.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Lactobacilli and vaginal host defense: activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF-kappaB.

J Infect Dis. 1999 Mar;179(3):653-60. Unique Identifier : AIDSLINE MED/99137801
Klebanoff SJ; Watts DH; Mehlin C; Headley CM; Department of Medicine, University of Washington, Seattle, WA; 98195-7185, USA. seym@u.washington.edu

Abstract: Lactobacilli, a component of the normal vaginal flora, can activate the human immunodeficiency virus (HIV)-1 long terminal repeat (LTR) in the Jurkat T lymphocyte and THP-1 macrophage cell lines. Activation of the LTR in Jurkat cells was strongly enhanced by vanadate and inhibited by catalase, implicating H2O2. In contrast, activation in THP-1 cells occurred in the absence of vanadate and was unaffected by catalase. The active material partitioned into the phenol layer on hot aqueous phenol extraction. Lactobacilli also increased tumor necrosis factor-alphaand interleukin-1betaproduction and activated NF-kappaB in THP-1 cells and increased tumor necrosis factor-alphaproduction by human monocytes. Human vaginal fluid specimens had comparable properties, which correlated with their bacterial content. These findings suggest the presence in vaginal fluid of agent(s) derived from indigenous bacteria that can activate the HIV-1 LTR, cytokine production, and NF-kappaB in cells of macrophage lineage, with possible influence on vaginal physiology and host defense.

Keywords: JOURNAL ARTICLE Catalase/PHARMACOLOGY Cell Line Cytokines/*BIOSYNTHESIS/GENETICS Female Gene Expression Regulation Human *HIV Long Terminal Repeat/DRUG EFFECTS HIV-1/GROWTH & DEVELOPMENT/GENETICS/*PHYSIOLOGY Interleukin-1/BIOSYNTHESIS Jurkat Cells Kinetics Lactobacillus/IMMUNOLOGY/*PHYSIOLOGY Macrophages Monocytes/MICROBIOLOGY/PHYSIOLOGY/VIROLOGY NF-kappa B/*METABOLISM Support, U.S. Gov't, P.H.S. T-Lymphocytes Tumor Necrosis Factor/BIOSYNTHESIS Vagina/*MICROBIOLOGY/VIROLOGY Vanadates/PHARMACOLOGY *Virus Activation
990630
A9960911

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .